News

2022’s Most & Least Innovative States

(WalletHub) – Innovation is a principal driver of U.S. economic growth. In 2022, the U.S. will spend nearly $600 billion on research and development — more than any other country in the world and more than 25% of the world’s total — helping the nation rank third on the Global Innovation Index. According to the results of the ranking, knowledge and technology outputs are America’s particular strengths. Some of the biggest innovations the U.S. has produced recently are the COVID-19 vaccines.

But certain states deserve more credit than others for America’s dominance in the tech era. These states continue to grow innovation through investments in education, research and business creation, especially in highly specialized industries.

In order to recognize the nation’s biggest contributors, WalletHub compared the 50 states and the District of Columbia across 22 key indicators of innovation-friendliness. Our data set ranges from share of STEM professionals to R&D spending per capita to tech-company density.

Read more here.

Recent News

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …

10/20/2026

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights …

10/16/2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company’s research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed for the …